TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF
Brief Summary: The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated with acquisition of Pa. This study will also collect and bank DNA samples for current and future studies designed to enhance the understanding of the pathogenesis of CF.


Options:
A: Arm Label: Observational; Type: N/A; Interventions: N/A
B: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
C: Arm Label: Cycled TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Cycled TOBI & oral ciprofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Arm Label: Culture based TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Culture based TOBI & oral cipro; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Intervention Type: DRUG; Name: Tobramycin solution for inhalation (TOBI); Assigned to Arm(s): Culture based TOBI & oral cipro, Culture based TOBI & placebo, Cycled TOBI & oral ciprofloxacin, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral placebo; Assigned to Arm(s): Culture based TOBI & placebo, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral ciprofloxacin; Assigned to Arm(s): Culture based TOBI & oral cipro, Cycled TOBI & oral ciprofloxacin
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF
Brief Summary: The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated with acquisition of Pa. This study will also collect and bank DNA samples for current and future studies designed to enhance the understanding of the pathogenesis of CF.


Options:
A: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
B: Arm Label: Observational; Type: N/A; Interventions: N/A
C: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)
D: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF
Brief Summary: The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated with acquisition of Pa. This study will also collect and bank DNA samples for current and future studies designed to enhance the understanding of the pathogenesis of CF.


Options:
A: Arm Label: Observational; Type: N/A; Interventions: N/A
B: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF
Brief Summary: The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated with acquisition of Pa. This study will also collect and bank DNA samples for current and future studies designed to enhance the understanding of the pathogenesis of CF.


Options:
A: Arm Label: 32.50 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: 48.75 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: Matching Placebo for 32.50 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Matching Placebo for 48.75 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 32.50 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 32.50 mg | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 48.75 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 48.75 mg
B: Arm Label: Observational; Type: N/A; Interventions: N/A
C: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)
D: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?
Brief Summary: Pilot study aiming to assess the effect of two doses of rhu EPO on urine NGAL concentration and on serum cystatin C and creatinine levels in critically ill patients at risk of ARF.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2
B: Arm Label: Sevoflurane Group; Type: N/A; Interventions: Drug: Sevoflurane | Arm Label: Not Sevoflurane Group; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane Group
C: Arm Label: Corticosteroid; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroid | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Corticosteroid
D: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?
Brief Summary: Pilot study aiming to assess the effect of two doses of rhu EPO on urine NGAL concentration and on serum cystatin C and creatinine levels in critically ill patients at risk of ARF.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% NaCl | Arm Label: verum; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin alfa | Intervention Type: DRUG; Name: recombinant human erythropoietin alfa; Assigned to Arm(s): verum | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): placebo
C: Arm Label: PCI only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: human recombinant erythropoietin | Intervention Type: DRUG; Name: human recombinant erythropoietin; Assigned to Arm(s): EPO
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EPO | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: EPO; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
C: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
B: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2

Answer: C